首页> 外文期刊>The American journal of emergency medicine >Myeloperoxidase and C-reactive protein in patients with cocaine-associated chest pain
【24h】

Myeloperoxidase and C-reactive protein in patients with cocaine-associated chest pain

机译:可卡因相关性胸痛患者的髓过氧化物酶和C反应蛋白

获取原文
获取原文并翻译 | 示例
           

摘要

Background Myeloperoxidase (MPO) and C-reactive protein (CRP) are markers of inflammation and elevated levels have been found in patients with acute coronary syndrome (ACS) unrelated to cocaine. We evaluated the utility of MPO and CRP for diagnosis of ACS and the prediction of 30-day adverse cardiovascular events in patients with cocaine-related chest pain. Methods This is a secondary analysis from a prospective cohort study of ED patients who received evaluation for ACS. Structured data collection at presentation included demographics, chest pain history, laboratory results, and electrocardiographic data. Our primary outcome was diagnosis of ACS at index visit and 30-day adverse events. As a secondary analysis, we provide data on a matched cohort without cocaine use. Results Baseline data and CRP were available for 95 cocaine users; 82 had MPO data also. Patients had a mean age of 46.6 (SD 8.1) years, 90% were black, and 62% were male. Acute coronary syndrome occurred in 7% of cocaine users. With respect to diagnosis of ACS, the area under the curve was poor for both MPO (0.65; 95% confidence interval [CI]: 0.40-0.91) and CRP (0.63; 95% CI: 0.39-0.88). Similar results were found for 30-day events. With respect to prognosis of 30-day adverse cardiovascular events, the area under the curve was 0.68 (95% CI: 0.45-0.91) for MPO and 0.67 (95% CI: 0.45-0.90) for CRP. Similar results were found for 30-day events. In the matched cohort of patients who were not cocaine users, performance of MPO (n = 66) and CRP (n = 86) was also poor. Conclusions Myeloperoxidase and CRP are not useful for diagnosis or prognosis of patients with cocaine-associated chest pain.
机译:背景髓过氧化物酶(MPO)和C反应蛋白(CRP)是炎症的标志物,在与可卡因无关的急性冠脉综合征(ACS)患者中发现了升高的水平。我们评估了MPO和CRP在可卡因相关性胸痛患者中诊断ACS和预测30天不良心血管事件的效用。方法这是一项对接受ACS评估的ED患者的前瞻性队列研究的二级分析。演讲中的结构化数据收集包括人口统计学,胸痛史,实验室检查结果和心电图数据。我们的主要结果是在就诊和30天不良事件诊断为ACS。作为辅助分析,我们提供了不使用可卡因的同类人群数据。结果95名可卡因使用者可获得基线数据和CRP。 82个也有MPO数据。患者平均年龄为46.6(SD 8.1)岁,黑人为90%,男性为62%。 7%的可卡因使用者发生了急性冠状动脉综合征。关于ACS的诊断,MPO(0.65; 95%置信区间[CI]:0.40-0.91)和CRP(0.63; 95%CI:0.39-0.88)的曲线下面积均较差。在30天的活动中发现了类似的结果。关于30天不良心血管事件的预后,MPO曲线下面积为0.68(95%CI:0.45-0.91),CRP为0.67(95%CI:0.45-0.90)。在30天的活动中发现了类似的结果。在非可卡因使用者的配对队列中,MPO(n = 66)和CRP(n = 86)的表现也很差。结论髓过氧化物酶和CRP不能用于可卡因相关性胸痛的诊断或预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号